CA2937487C - Stabilized thrombin compositions - Google Patents

Stabilized thrombin compositions Download PDF

Info

Publication number
CA2937487C
CA2937487C CA2937487A CA2937487A CA2937487C CA 2937487 C CA2937487 C CA 2937487C CA 2937487 A CA2937487 A CA 2937487A CA 2937487 A CA2937487 A CA 2937487A CA 2937487 C CA2937487 C CA 2937487C
Authority
CA
Canada
Prior art keywords
concentration
sucrose
solution
composition
thrombin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2937487A
Other languages
English (en)
French (fr)
Other versions
CA2937487A1 (en
Inventor
Richard I. Senderoff
Shan Jiang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Mallinckrodt Pharma IP Trading DAC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Pharma IP Trading DAC filed Critical Mallinckrodt Pharma IP Trading DAC
Publication of CA2937487A1 publication Critical patent/CA2937487A1/en
Application granted granted Critical
Publication of CA2937487C publication Critical patent/CA2937487C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2937487A 2007-06-15 2008-06-13 Stabilized thrombin compositions Active CA2937487C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94422407P 2007-06-15 2007-06-15
US60/944,224 2007-06-15
CA2687968A CA2687968C (en) 2007-06-15 2008-06-13 Stabilized thrombin compositions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2687968A Division CA2687968C (en) 2007-06-15 2008-06-13 Stabilized thrombin compositions

Publications (2)

Publication Number Publication Date
CA2937487A1 CA2937487A1 (en) 2008-12-24
CA2937487C true CA2937487C (en) 2018-01-09

Family

ID=40132545

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2937487A Active CA2937487C (en) 2007-06-15 2008-06-13 Stabilized thrombin compositions
CA2687968A Active CA2687968C (en) 2007-06-15 2008-06-13 Stabilized thrombin compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2687968A Active CA2687968C (en) 2007-06-15 2008-06-13 Stabilized thrombin compositions

Country Status (8)

Country Link
US (1) US8071090B2 (https=)
EP (1) EP2167041B1 (https=)
JP (1) JP5253501B2 (https=)
AU (1) AU2008266094B2 (https=)
CA (2) CA2937487C (https=)
ES (1) ES2397234T3 (https=)
IL (1) IL202306A (https=)
WO (1) WO2008157304A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE554397T1 (de) * 2006-12-21 2012-05-15 Sekisui Medical Co Ltd Verfahren zur stabilisierung von alpha-thrombin in einer thrombinhaltigen lösung
RU2657955C2 (ru) 2012-03-06 2018-06-18 Ферросан Медикал Дивайсиз А/С Контейнер под давлением, содержащий гемостатическую пасту
EP2977066A3 (en) 2012-06-12 2016-07-27 Ferrosan Medical Devices A/S Dry haemostatic composition
US9149529B2 (en) 2012-10-24 2015-10-06 Orthovita, Inc. Stable compositions containing thrombin and methods for preparation and use thereof
AU2014283170B2 (en) 2013-06-21 2017-11-02 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
IL229134A0 (en) 2013-10-29 2014-03-31 Omrix Biopharmaceuticals Ltd Compounds and methods for stabilizing thrombin activity
JP6489485B2 (ja) 2013-12-11 2019-03-27 フェロサン メディカル デバイシーズ エイ/エス 押し出し増強因子を含んでいる乾燥組成物
IL234246A0 (en) * 2014-08-21 2014-11-30 Omrix Biopharmaceuticals Ltd Stabilized thrombin
AU2015333206B2 (en) 2014-10-13 2019-07-11 Ferrosan Medical Devices A/S. Dry composition for use in haemostasis and wound healing
RU2705905C2 (ru) 2014-12-24 2019-11-12 Ферросан Медикал Дивайсиз А/С Шприц для удерживания и смешивания первого и второго веществ
CA2970223A1 (en) * 2015-03-13 2016-09-22 Chung Chin Sun Method of stabilizing thrombin and composition thereof
CN107771093B (zh) 2015-07-03 2021-06-15 弗罗桑医疗设备公司 用于混合两种组分和用于在存储条件下保持真空的注射器
US11801324B2 (en) 2018-05-09 2023-10-31 Ferrosan Medical Devices A/S Method for preparing a haemostatic composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3879369A (en) 1972-05-12 1975-04-22 Abbott Lab Anti-coagulant isolation from malayan pit viper using affinity chromatography
US4696812A (en) 1985-10-28 1987-09-29 Warner-Lambert Company Thrombin preparations
JPS6440433A (en) 1987-08-05 1989-02-10 Green Cross Corp Aqueous liquid composition of thrombin
US5707996A (en) * 1995-11-06 1998-01-13 Macleod Pharmaceuticals, Inc. Pharmaceutical solution and methods for preparation thereof
EP1475098B1 (en) 2002-01-18 2015-08-05 Asahi Kasei Pharma Corporation High-concentration preparation of soluble thrombomodulin
WO2003086332A1 (en) * 2002-04-11 2003-10-23 Dvm Pharmaceuticals, Inc. Antimicrobial wash and carrier solutions, and uses thereof
WO2006009989A1 (en) 2004-06-22 2006-01-26 Zymogenetics, Inc. Thrombin compositions
US20060270015A1 (en) * 2005-05-26 2006-11-30 Dan Pawlak Thrombin purification
JP2006160760A (ja) * 2006-02-03 2006-06-22 Tobishi Pharmaceut Co Ltd 血管壁内膜肥厚抑制剤

Also Published As

Publication number Publication date
IL202306A0 (en) 2010-06-30
WO2008157304A2 (en) 2008-12-24
AU2008266094B2 (en) 2014-01-30
WO2008157304A3 (en) 2009-03-12
EP2167041B1 (en) 2012-11-07
CA2687968C (en) 2016-09-27
JP5253501B2 (ja) 2013-07-31
IL202306A (en) 2014-07-31
JP2010529997A (ja) 2010-09-02
AU2008266094A1 (en) 2008-12-24
EP2167041A2 (en) 2010-03-31
US8071090B2 (en) 2011-12-06
US20080311104A1 (en) 2008-12-18
CA2687968A1 (en) 2008-12-24
CA2937487A1 (en) 2008-12-24
ES2397234T3 (es) 2013-03-05
AU2008266094A8 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
CA2937487C (en) Stabilized thrombin compositions
US7473543B2 (en) Thrombin compositions
US4696812A (en) Thrombin preparations
CA2171266C (en) Stable transglutaminase preparations and processes for producing them
JP2006257099A (ja) 高度に濃縮された、凍結乾燥された、および液体の、因子ix処方
AU2015367185B2 (en) Pharmaceutical composition comprising plasminogen and uses thereof
TR201809670T4 (tr) Faktör VII polipeptitlerinin stabilize edilmiş kompozisyonları.
HU215263B (hu) VIII faktor csökkentett oxigéntartalmú vizes oldata
TW201722459A (zh) 凍乾的重組vwf調配物
JPWO1995016460A1 (ja) 可溶性トロンボモジュリン含有組成物
IE59060B1 (en) Stabilized human tissue plasminogen activator compositions
CN112566624A (zh) 稳定的液体凝血酶组合物
ES2407134T3 (es) Composiciones hemostáticas farmacéuticamente estables
JP2837847B2 (ja) トロンビン製剤
EP1927658B1 (en) Thrombin compositions
US20240189398A1 (en) Liquid composition comprising factor viii or factor viii/von willebrand factor complex
HK40049456A (en) Stable liquid thrombin compositions

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160729

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20241213